Pierre Pfitzenmeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pierre Pfitzenmeyer has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bernard Lorcerie
Service de médecine interne et immunologie clinique, hôpital du Bocage, CHU de Dijon, 2, boulevard du Maréchal-de-Lattre-de-Tassigny, BP 77908, 21079 Dijon cedex, France
1 shared publication - Géraldine Muller
Department of Internal Medicine and Systemic Diseases, General Hospital, University Hospital, Dijon Cedex, France
1 shared publication - Jean-François Besancenot
Department of Internal Medicine and Systemic Diseases, General Hospital, University Hospital, Dijon Cedex, France
1 shared publication - Julien Vinit
Department of Internal Medicine and Systemic Diseases, General Hospital, University Hospital, Dijon Cedex, France
1 shared publication - Philip Bielefeld
Department of Internal Medicine, Dijon Bourgogne University Hospital, F-21000 Dijon, France
1 shared publication - Philippe Bonniaud
Institut Universitaire du Poumon, Centre de Référence Constitutif des Maladies Pulmonaires Rares de l’Adulte, Centre Hospitalo-Universitaire Dijon-Bourgogne, 21000 Dijon, France
1 shared publication
Latest Publications
- 29 December 2009
- Published by Springer Nature in Rheumatology International
- Vol. 31 (5) , 587-593
Churg–Strauss syndrome: retrospective study in Burgundian population in France in past 10 years
Churg–Strauss Syndrome (SCS) is a systemic vasculitis associated with asthma and eosinophilia. The aim of our work is to describe this pathology in the Burgundian population in France. We counted from the hospitalisation data-processing summaries, the whole of the SCS hospitalised in Burgundy between 1998 and 2008. During the follow-up, the clinical and paraclinical characteristics of every patient were collected. The average prevalence is of 11.3 per million inhabitants and the incidence is of 1.2 new cases per million inhabitants per annum. There exists however, a great prevalence disparity and incidence amongst the various departments of the area. The patient’s average follow-up is of 7.7 years. In 23% of the cases one finds a starting factor for vasculitis. The delay between the first signs and the diagnostic is an average of 61 months. The ANCA are positive in 26% of cases and of anti-myeloperoxidase specificity in 83% of cases (P < 0.001). The most profitable biopsies are essentially cutaneous and neuromuscular. At the diagnostic, two-third of the patients have had a treatment adapted according to the current recommendations based on the Five Factor Score. The remission rate within a 1-year period is of 77%. The remission is strongly correlated to the therapeutic protocol associating corticoids and cyclophosphamide (P < 0.05). In conclusion, the prevalence of SCS in our area is similar to that observed in other European regions. However, this vasculitis remains a difficult and often a tardive diagnostic pathology.
- 29 December 2009
- Published by Springer Nature in Rheumatology International
- Vol. 31 (5) , 587-593
Churg–Strauss syndrome: retrospective study in Burgundian population in France in past 10 years
Churg–Strauss Syndrome (SCS) is a systemic vasculitis associated with asthma and eosinophilia. The aim of our work is to describe this pathology in the Burgundian population in France. We counted from the hospitalisation data-processing summaries, the whole of the SCS hospitalised in Burgundy between 1998 and 2008. During the follow-up, the clinical and paraclinical characteristics of every patient were collected. The average prevalence is of 11.3 per million inhabitants and the incidence is of 1.2 new cases per million inhabitants per annum. There exists however, a great prevalence disparity and incidence amongst the various departments of the area. The patient’s average follow-up is of 7.7 years. In 23% of the cases one finds a starting factor for vasculitis. The delay between the first signs and the diagnostic is an average of 61 months. The ANCA are positive in 26% of cases and of anti-myeloperoxidase specificity in 83% of cases (P < 0.001). The most profitable biopsies are essentially cutaneous and neuromuscular. At the diagnostic, two-third of the patients have had a treatment adapted according to the current recommendations based on the Five Factor Score. The remission rate within a 1-year period is of 77%. The remission is strongly correlated to the therapeutic protocol associating corticoids and cyclophosphamide (P < 0.05). In conclusion, the prevalence of SCS in our area is similar to that observed in other European regions. However, this vasculitis remains a difficult and often a tardive diagnostic pathology.